Friday, 13 November 2026European Markets

VANTIVA Stock Bullish By 15% In The Last 5 Sessions

Loading stream...

(vianews) - shares of vantiva (cac 40: vanti.pa) jumped by a staggering 15.72% in 5 sessions from €0.21 to €0.24 at 17:12 est on tuesday, after three consecutive sessions in a row of gains. cac 40 is rising 0.26% to €7,364.77, after five consecutive sessions in a row of gains.

about vantiva

vantiva s.a. develops, creates, and delivers products and services for the media and entertainment sectors in france, the united kingdom, rest of europe, the united states, rest of americas, and the asia-pacific. it operates through three segments: technicolor creative studios, dvd services, and connected home. the technicolor creative studios segment offers high-end services to content creators, including visual effects and animation for features films, episodic series, advertising, video games, and other audiovisual content. the dvd services segment replicates, packages, and distributes video game and music cd, dvd, and blu-ray discs; and provides turnkey integrated supply-chain solutions comprising distribution, fulfillment, freight-brokerage, and transportation management services, as well as inventory management and related services. the connected home segment offers a portfolio of broadband and video customer premise equipment, including broadband modems and gateways, digital set-top boxes, and internet of things connected devices for pay-tv operators and network service providers, as well as develops software solutions. the company was formerly known as technicolor sa and changed its name to vantiva s.a. in september 2022. vantiva s.a. was incorporated in 1985 and is headquartered in paris, france.

stock price classification

according to the stochastic oscillator, a useful indicator of overbought and oversold conditions, vantiva's stock is considered to be oversold (<=20).

more news about vantiva (vanti.pa).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Biotech Catalyst Wave: Late-2026 Clinical Readouts, PDUFA Dates and Capital Restructuring
A dense cluster of Q4 2026 to Q1 2027 clinical and regulatory catalysts spans hepatitis delta (Vir's ECLIPSE/SOLSTICE), hypertension and sleep apnea (Mineralys' lorundrostat, PDUFA 2026-12-22), severe hypertriglyceridemia (plozasiran), oncology (ivonescimab BLA, PDUFA 2026-11-14) and gene therapy (Krystal). Positive data flow from AASLD and AHA presentations is offset by cost-cutting guidance, milestones slipping into 2027, and a delisting process that signals capital-market stress for some issuers. Near-term value hinges on binary FDA decisions and Phase 3 topline readouts in Q1 2027.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,995
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,995 facts checked against source5,565 source documents archived
Query this data → isubstrate.com